Kodiak Sciences (KOD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

KOD · Stock Price

USD 43.68+39.91 (+1058.62%)

Market Cap: $2.6B

Historical price data

Market Cap: $2.6BPipeline: 11 drugs (10 Phase 3)Patents: 12Founded: 2009Employees: 100-250HQ: Palo Alto, United States

Sector Ranking#84 in Biologics / Biosimilars #31 in Drug Delivery & Formulation

Overview

Kodiak Sciences is a clinical-stage biopharma company with a mission to prevent and treat the leading causes of blindness through its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company has achieved significant milestones, including positive Phase 3 topline results for its lead asset, Zenkuda (tarcocimab tedromer), in diabetic retinopathy and a BLA-ready profile. Its strategy is built on a deep, focused commitment to ophthalmology, leveraging its platform to develop durable, multi-mechanistic therapies that address fundamental unmet needs in retinal disease management.

OphthalmologyRetinal Diseases

Technology Platform

Proprietary Antibody Biopolymer Conjugate (ABC/ABCD) Platform, which uses a bio-inspired polymer to create a protective shield around therapeutic proteins, enabling extended durability and multi-mechanistic targeting in retinal diseases.

Pipeline

11

11 drugs in pipeline10 in Phase 3

Drug	Indication	Stage
KSI-301 + Aflibercept	Wet Age-related Macular Degeneration	Phase 3
KSI-301 + Aflibercept	Diabetic Macular Edema	Phase 3
KSI-301	Non-proliferative Diabetic Retinopathy	Phase 3
Tarcocimab	Diabetic Retinopathy	Phase 3
Tarcocimab tedromer + Tabirafusp tedromer + Aflibercept	Wet Age-related Macular Degeneration	Phase 3

Funding History

4

Total raised:$525M

PIPE$225MBaker Bros. AdvisorsDec 15, 2020

IPO$150MUndisclosedOct 18, 2018

Series B$100MBaker Bros. AdvisorsJan 15, 2018

Series A$50MClarus VenturesJan 15, 2015

Opportunities

The primary opportunity lies in capturing significant market share in multi-billion dollar retinal disease markets by introducing therapies with superior durability (4-6 month dosing) and novel, combination mechanisms.

Successfully launching Zenkuda could establish a new 'mainstay' therapy, while KSI-101 has first-mover potential in the untreated inflammatory macular edema (MESI) segment.

Risk Factors

Key risks include clinical/regulatory setbacks for late-stage candidates, intense competition from established and novel therapies, the challenge of commercializing in a crowded market, and potential future dilution as the company funds its transition to commercialization.

The novel ABC platform also carries inherent technical and CMC validation risks.

Competitive Landscape

Kodiak faces competition from major pharma (Roche, Regeneron, Novartis) with dominant anti-VEGF therapies and from biotechs advancing extended-duration formulations, gene therapies, and new mechanisms. Its differentiation is its platform-based approach to building durability directly into the biologic and its pursuit of dual-mechanism (VEGF/IL-6) bispecifics for enhanced efficacy.